Plain-English translation of NCT07303803 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can help treat metabolic dysfunction-associated steatohepatitis (fatty liver disease) in people who also have type 2 diabetes. The medication is designed to work on three important pathways in the body: how you process fats, how your blood sugar is controlled, and inflammation. You would take this treatment along with and another supportive therapy for 72 weeks.
Fatty liver disease combined with type 2 diabetes is a serious condition that can lead to lasting liver damage, but there aren't many proven treatment options specifically for people with both conditions. This study is testing whether this medication could fill that gap and help prevent the liver from getting worse.
You likely qualify if…
You likely don't qualify if…
You would visit the study center multiple times over 72 weeks (about 18 months). At each visit, you'll have blood tests and possibly imaging scans to check your liver and overall health. You'll take one pill of either the new medication or a placebo daily, along with two other supportive medications ( and another liver-protective agent). The study is double-blind, meaning neither you nor the doctors will know whether you're receiving the new medication or placebo until the study ends.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China